comparemela.com

Latest Breaking News On - Zhongshan hospital affiliated - Page 1 : comparemela.com

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

United statesHong kongYong huoEli lillyEquecabtagene autoleucelYujie zhouInnovent biologicsAdimab incyteIncyte corporationUniversity first hospitalAnzhen hospital affiliated to capital medical universityMd anderson cancer centerZhongshan hospital affiliated to fudan universityChina national medical products administrationChina cardiovascular healthClinical development of innovent

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

/PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and.

Hong kongSoochow universityT ai peiZhu dumingRogers yongqing luoCritical care department at zhongshan hospitalInnoviva incFudan universityNational medical products administrationFirst affiliated hospital of soochow universityTetraphase pharmaceuticals incHuashan hospitalChief executive officerCritical care departmentZhongshan hospital affiliatedCarbapenem resistant organism

Kintor Announces 2022 Interim Results and Recent Business Update

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma" or "the Company", HKEX: 9939), a clinical-stage biotechnology company developing innovative.

United statesHong kongFederation of bosnia and herzegovinaBosnia herzegovinaMacau generalRepublic of ghanaKintor pharmaJianzhong zhangHong kong stock connect programMinistry of healthKintor pharmaceuticalGuangdong provincial department of human resourcesMost influential small molecule innovative drug companiesTechnology innovation support plan for international scienceJiangsu provincial department of scienceTechnology cooperation hong kong

Human trials for Chinese mRNA vaccine set to begin in China

The phase I clinical trial of the COVID-19 mRNA vaccine developed by a Shanghai-based biotechnology firm has completed patient enrollment in China, according to a report by online news portal ThePaper.cn.

Shen haifaZhongshan hospital affiliated to fudan universityStemirna therapeuticsZhongshan hospital affiliatedFudan universityCovid 19

Filling gap in market: VenusP-Valve™ approved by China s NMPA

/PRNewswire/ On July 11, 2022, VenusP-ValveTM, Venus Medtech s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was.

United statesEric ziVenus medtechVenus medtech hangzhou incDevelopment programNational key researchSichuan universityJapan us harmonization by doing programInvestigator meetingDoing programNorth americaFirst prizeTechnical invention awardExcellent achievementsScientific researchHigher education

vimarsana © 2020. All Rights Reserved.